Metastatic non-small-cell lung cancer: Consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1507-1519

  Felip, E ^a   Gridelli, C ^b   Baas, P ^c   Rosell, R ^d   Stahel, R ^e  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b S G MOSCATI HOSPITAL   (Italy)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BRCA1 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; K RAS PROTEIN; MESSENGER RNA; MITOMYCIN; NAVELBINE; ONCOPROTEIN; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; PROTEIN PIK3CA; PROTEIN RRM1; PROTEIN TS; UNCLASSIFIED DRUG; VINBLASTINE;

ADVANCED CANCER; AGE DISTRIBUTION; AGING; ANAPLASTIC LYMPHOMA KINASE GENE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSENSUS DEVELOPMENT; DRUG CHOICE; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; EML4 GENE; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; METASTASIS POTENTIAL; MOLECULAR DIAGNOSIS; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NATIONAL HEALTH ORGANIZATION; NAUSEA; NEPHROTOXICITY; ONSET AGE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; SOMATIC MUTATION; SYSTEMIC THERAPY; TREATMENT PLANNING;

EID: 79959703683     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr150     Document Type: Article

References (78)

1. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
2. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010; 10: 241-253.
3. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
4. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
5. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
6. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non small cell lung cancer with mutated tumour. N Engl J Med 2010; 362: 2380-2388.
7. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
8. Pirker R, Herth FJ, Kerr KM et al. Consensus for EGFR mutation testing in nonsmall cell lung cancer: results from a European workshop. J Thorac Oncol 2010; 5: 1706-1713.
9. Garcia-Olive I, Monso E, Andreo F et al. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 2010; 35: 391-395.
10. Travis WD, Rekhtman N, Riley GJ et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010; 5: 411-414.
11. Solomon SB, Zakowski MF, Pao W et al. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol 2010; 194: 266-269.
12. Motoi N, Szoke J, Riely GJ et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-827.
13. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 5: 244-285.
14. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009; 54: 12-27.
15. Paez JG, Jä nne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
16. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
17. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "ever smokers"and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-13311.
18. Rosell R, Molina M, Costa C et al. Outcome to erlotinib in non-small-cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies. J Clin Oncol 2010; 28: 542s (Abstr 7514).
19. Inukai M, Toyooka S, Ito S et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006; 66: 7854-7858.
20. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-377.
21. Cappuzzo F, Coudert B, Wierzbicki R et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised placebocontrolled phase 3 study. Lancet Oncol 2010; 11: 521-529.
22. Ramsden SC, Deans Z, Robinson DO et al. Monitoring standards for molecular genetic testing in the United Kingdom, the Netherlands, and Ireland. Genet Test 2006; 10: 147-156.
23. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
24. Camidge DR, Kono SA, Flacco A et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010; 16: 5581-5590.
25. Rodig SJ, Mino-Kenudson M, Dacic S et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15: 5216-5223.
26. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
27. Yamamoto H, Shigematsu H, Nomura M et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008; 68: 6913-6921.
28. Shigematsu H, Takahashi T, Nomura M et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65: 1642-1646.
29. Mounawar M, Mukeria A, Le Calvez F et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 2007; 67: 5667-5672.
30. Schmid K, Oehl N, Wrba F et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009; 15: 4554-4560.
31. Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in nonsmall-cell lung cancer. J Clin Oncol 2007; 25: 2747-2754.
32. Rosell R, Scagliotti G, Danenberg KD et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003; 22: 3548-3553.
33. Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17: 1818-1825.
34. Quinn JE, Kennedy RD, Mullan PB et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221-6228.
35. Taron M, Rosell R, Felip E et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13: 2443-2449.
36. Boukovinas I, Papadaki C, Mendez P et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS ONE 2008; 3: e3695.
37. Rosell R, Perez-Roca L, Sanchez JJ et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 2009; 4: e5133.
38. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
39. Brenner H, Francisci S, de Angelis R et al. Long-term survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer 2009; 45: 1028-1041.
40. SCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non small cell lung cancer: a systematic review and meta-analysis of individual patient data of 16 controlled clinical trials. J Clin Oncol 2008; 26: 4617-4625.
41. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 66-72.
42. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 591-598.
43. D'Addario G, Pintilie M, Leighl MB et al. Platinum-based versus non-platinumbased chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-2936.
44. Pujol JL, Barlesi F, Daures JP. Should chemotherapy combination for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006; 51: 335-345.
45. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non small cell lung cancer. J Clin Oncol 2004; 22: 3852-3859.
46. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-857.
47. Gridelli C, Ardizzoni A, Le Chavalier T et al. Treatment of advanced non-smallcell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004; 15: 419-426.
48. Lilenbaum R, Villaflor VM, Langer C et al. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol 2009; 4: 869-874.
49. Langer CJ, O'Byrne KJ, Socinski MA et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapynai{dotless} ̈ve advanced non-small cell lung cancer. J Thorac Oncol 2008; 3: 623-630.
50. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
51. Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-181.
52. Quoix EA, Oster J, Pichon E et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients aged 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28(15s): 5s (Abstr 2).
53. Schiller J, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N Engl J Med 2002; 346: 92-98.
54. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin in advanced non small cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024.
55. Scagliotti G, de Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non small cell lung. J Clin Oncol 2002; 20: 4285-4291.
56. Scagliotti G, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
57. Smith IE, O'Brien ME, Talbot DC et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19: 1336-1343.
58. von Plessen C, Bergman B, Andresen O et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006; 95: 966-973.
59. Gridelli C, Maione P, Rossi A et al. Potential treatment options after first-line chemotherapy for advanced non small cell lung cancer: maintenance treatment or early second-line? Oncologist 2009; 14: 137-147.
60. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
61. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
62. Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804-1809.
63. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
64. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28: 911-917.
65. Thatcher N, Lynch TJ, Butts CA et al. Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small-cell lung cancer: a meta-analysis of randomized phase II/III trials. J Thorac Oncol 2009; 4 (Suppl 1): S297.
66. O'Byrne KJ, von Pawel J, Vynnychenko I et al. First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer receiving first-line chemotherapy plus cetuximab: efficacy by histology. J Clin Oncol 2010; 28 (Suppl 1): 7s.
67. Zhou C, Wung YI, Chen G et al. on behalf of the OPTIMAL investigators. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in chinese advanced nonsmall-cell lung cancer patients with EGFR activating mutations. Ann Oncol 2010; 21 (Suppl 8): (Abstr LBA13).
68. Walbert T, Gilbert MR. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 2009; 14: 299-306.
69. Robinet G, Thomas P, Breton JL et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francxais de Pneumo-Cancé rologie (GFPC) Protocol 95-1. Ann Oncol 2001; 12: 59-67.
70. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
71. Hanna N, Shepherd FA, Fosella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 9: 1589-1597.
72. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
73. Di Maio M, Chiodini P, Georgoulias V et al. Meta-analysis of single agent chemotherapy compared with combination therapy as second line treatment of advanced lung cancer. J Clin Oncol 2009; 27: 1836-1843.
74. Massarelli E, Andre L, Liu DD et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003; 39: 55-61.
75. Hotta H, Kiura K, Ueoka M et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 46: 255-256.
76. Wu CH, Fan WC, Chen YM et al. Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients. J Thorac Oncol 2010; 5: 376-379.
77. Weis GJ, Langer C, Rosell R et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 4405-4411.
78. Kim SE, Hirch V, Mok T et al. Gefitinib versus docetaxel in previously treated patients with non-small-cell-lung-cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372: 1809-1818.